A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- University of Alabama at Birmingham
- Study ID
- NCT06240351
- Phase
- PHASE4
- Status
- Active Not Recruiting
Conditions
- Frontal Fibrosing Alopecia
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- Baricitinib 4 MG Oral Tablet — DRUGBaricitinib is a Janus kinase (JAK) inhibitor
Study Details
The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in the treatment of frontal fibrosing alopecia (FFA).
Key Dates
- Start date
- Apr 22, 2024
- Status verified
- Jan 2026
- Primary completion
- Jul 31, 2026
- Completion
- Jul 31, 2027
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: BaricitinibAll patients will be treated with the active product, Baricitinib. Each patient will take 4mg of Baricitinib daily for 36 weeks.
Primary Outcome Measure
30% Change in Lichen Planopilaris Activity (LPPAI) Scores [ Time Frame: From baseline to week 12, 24, and 36 ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | - |
Find similar trials in Birmingham, AL
By research site
Related Studies
- Facial Papules in Frontal Fibrosing Alopecia (FFA)Not Yet Recruiting · University of Miami · Miami, Florida
- Deucravacitinib in the Treatment of Cicatricial AlopeciasPHASE2 · Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York